African Journal of
Biotechnology

  • Abbreviation: Afr. J. Biotechnol.
  • Language: English
  • ISSN: 1684-5315
  • DOI: 10.5897/AJB
  • Start Year: 2002
  • Published Articles: 12481

Full Length Research Paper

Ultrasound sensitizes chemotherapy in chemoresistant ovarian cancers

  Yi Lou1#, Yi Zhang2#, Haining He2, Yingfen Liu2, Ping Huang3 and Tinghe Yu1,2*         #Both authors contributed equally.
  1Institute of Life Science, Chongqing Medical University, Chongqing, China. 2Laboratory of Biomedical Ultrasonics, West China Institute of Women and Children’s Health, West China Second University Hospital, Sichuan University, Chengdu, China. 3Department of General Surgery, The First Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Email: [email protected]

  •  Accepted: 20 May 2011
  •  Published: 26 September 2011

Abstract

 

Chemotherapy resistance is still a great challenge to the management of ovarian cancers. Using SKOV3/ADR or COC1/DDP subline as a model of adriamycin- or cisplatin-resistance, ultrasonic chemosensitization was investigated. The addition of noncytotoxic insonation led to a higher cell-death rate as compared with a drug alone. Ultrasound sensitized chemotherapy via increasing intracellular drug accumulation, enhancing drug-induced apoptosis and decreasing the threshold dose for cell apoptosis/necrosis. Ultrasound exposure enhanced cisplatin-induced DNA breakages in COC1/DDP cells but did not decrease the level of glutathione-S-transferase. Chemosensitization attributable to insonation was mostly mediated by cavitation. Ultrasonic chemotherapy had the property of a targeted treatment, in that the dose-anticancer effect and dose-toxicity curves differed from those in conventional chemotherapy. The findings indicated that ultrasound was a non-drug modality for sensitizing chemotherapy in refractory ovarian cancers.

 

Key words: Chemoresistance, ovarian cancer, ultrasound, sonochemotherapy, targeted therapy.